US EditionPublished • loading... • Updated
AstraZeneca Pledges £300 Million UK Investment After Trade Deal
The company said the spending follows a trade agreement with the United States and comes after it paused and abandoned major UK projects.
- On Wednesday, Prime Minister Keir Starmer announced that AstraZeneca will invest £300 million in UK life sciences, aiming to future-proof thousands of jobs in Macclesfield and Cambridge.
- Last year, AstraZeneca paused a £200 million expansion in Cambridge and scrapped plans for a £450 million vaccine plant in Merseyside, citing an inability to make projects economically viable.
- The investment follows a pharmaceutical arrangement struck with the United States, which AstraZeneca CEO Pascal Soriot stated ensures "increased spending on new medicines" and drives access to therapies.
- AstraZeneca reported a 12% rise in first-quarter revenues to $14.38 billion, with Soriot attributing the results to "consistent commercial execution" and keeping the company on track for 2030 targets.
- Since the UK-US deal, 13 pharmaceutical companies have committed £1.575 billion in inward investment, with Richard Torbett, CEO of the Association of the British Pharmaceutical Industry , calling April a "remarkable month" for the sector.
Insights by Ground AI
11 Articles
11 Articles
AstraZeneca announces surprise U-turn with plan to inject Britain with massive £300m splurge
AstraZeneca has announced a surprise U-turn on investment into the UK - and will press ahead with a major £300million spend.The pharmaceutical giant last year paused a planned £200million expansion of its research site in Cambridge, and scrapped plans to invest £450million in a Merseyside vaccine plant.In February 2025, AstraZeneca chief executive Pascal Soriot said the firm "couldn’t make the business case work and couldn’t make the investment …
·London, United Kingdom
Read Full Article
Initiative happens after the company paused large-scale projects last year
·Brazil
Read Full ArticleCoverage Details
Total News Sources11
Leaning Left2Leaning Right2Center3Last UpdatedBias Distribution43% Center
Bias Distribution
- 43% of the sources are Center
43% Center
L 29%
C 43%
R 28%
Factuality
To view factuality data please Upgrade to Premium
